deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT05618613

Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer (ELONA)

An Open-Label, Phase 1b-2 Study of Elacestrant, in Combination With Onapristone in Patients With Estrogen Receptor-Positive, Progesterone Receptor-Positive, HER2-negative Advanced or Metastatic Breast Cancer (ELONA)

Sponsor: Context Therapeutics Inc.

Conditions Breast Cancer
Interventions Elacestrant Onapristone
Updated 7 times since 2022 Last updated: May 6, 2025 Started: Dec 2, 2022 Primary completion: Jun 23, 2023 Completion: Jun 23, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Sponsor decision to discontinue onapristone development.

Other terminated trials from Context Therapeutics Inc.

More terminations from Context Therapeutics Inc.

Other Breast Cancer trials with similar outcome

Browse all Breast Cancer trials

This PHASE1/PHASE2 trial investigates Breast Cancer and is currently terminated or withdrawn. Context Therapeutics Inc. leads this study, which shows 7 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshotNot Yet Recruiting~Jan 2023 – ~Feb 2023 · 31 days · monthly snapshotRecruiting~Feb 2023 – ~Apr 2023 · 59 days · monthly snapshotRecruiting~Apr 2023 – ~Jul 2024 · 15 months · monthly snapshotActive Not Recruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotActive Not Recruiting~Sep 2024 – ~Jun 2025 · 9 months · monthly snapshotActive Not Recruiting~Jun 2025 – present · 12 months · monthly snapshotTerminated

Change History

7 versions recorded

  1. Jun 2025 — Present [monthly]

    Terminated PHASE1/PHASE2

    Status: Active Not Recruiting → Terminated

  2. Sep 2024 — Jun 2025 [monthly]

    Active Not Recruiting PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. Apr 2023 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  5. Feb 2023 — Apr 2023 [monthly]

    Recruiting PHASE1_PHASE2

▶ Show 2 earlier versions

  1. Jan 2023 — Feb 2023 [monthly]

    Recruiting PHASE1_PHASE2

    Status: Not Yet Recruiting → Recruiting

  2. Dec 2022 — Jan 2023 [monthly]

    Not Yet Recruiting PHASE1_PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Context Therapeutics Inc.
Data source: Context Therapeutics Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations